Use of ADCC-optimized antibodies for treating weak patients
The invention concerns the use of human or humanized chimeric monoclonal antibodies which are produced in selected cell lines, said antibodies bringing about a high ADCC activity as well as a high secretion of cytokines and interleukins, for treating underpopulations of so-called weak-response patients exhibiting CD16 FCGR3A-158F homozygote or FCGR3A-158V/F heterozygote polymorphism.
1. A method for treating haemolytic disease of the Previously Presentedborn, Sezary Syndrome, chronic myeloid leukaemias, chronic lymphoid leukaemias (CLL-B), cancer, breast cancer, conditions related to the environment, infectious diseases, chronic fatigue syndrome (CFS), parasitic infections, or viral infections, comprising:
administering a composition of antibodies specific to the condition to be treated to a patient homozygous for phenylalanine in position 158 of CD16 (FCGR3A-158F homozygotes) or a patient heterozygous for valine/pheynylalanine in position 158 of CD16 (FCGR3A-158V/F),
wherein said antibodies have a biantenary-type Fc domain glycosylation, and
wherein the concentration for the forms G0F+G1F is lower than 30%.
2. The method according to claim 1 , wherein the dose of said antibody composition administered to the patient is between 2 and 100 times lower than a dose of an antibody composition of the same specificity but of different glycosylation or produced in a CHO line.
3. The method according to claim 2 , wherein the dose of said antibody composition administered to the patient is between 5 and 25 times lower than a dose of an antibody composition of the same specificity but of different glycosylation or produced in a CHO line.
4. The method according to claim 1 , wherein the antibodies are directed against a non-ubiquitous antigen present in healthy donor cells or an antigen of a pathological cell or of an organism pathogenic for humans.
5. The method according to claim 1 , wherein the antibodies are anti-HLA-DR.
6. The method according to claim 1 , wherein the antibodies are anti-CD20.
7. The method according to claim 1 , wherein said method is for treating a cancer or an infection by a pathogenic agent.
8. The method according to claim 1 , wherein the antibodies are selected from the group consisting of anti-HLA-DR, anti-CD20, anti Ep-CAM, anti HER2, anti CD52, anti HER1, anti GD3, anti CA125, anti GD, anti GD2, anti CD-23 and anti Protein C, anti-KIR3DL2, anti-EGFR, anti-CD25, anti-CD38, anti-CD30, anti-CD33, and anti-CD44 and anti-viral antibodies.
9. The method according to claim 1 , wherein said method is for treating a cancer of positive HLA class-II cells, B-cell lymphomas, acute B-cell leukaemias, Burkitt's syndrome, Hodgkin's lymphoma, myeloid leukaemias, chronic B-cell lymphoid leukaemias (CLL-B), non-Hodgkin's T-cell leukaemias and lymphomas and chronic myeloid leukaemias.
10. The method according to claim 1 , wherein the condition and the antibody composition are selected from:
colorectal cancer and anti Ep-CAM antibody composition;
B cell lymphoma thrombocytopenia purpura and anti-CD20 antibody composition; ovarian cancer and anti-HER2 antibody composition;
RSV and palivizumab antibody composition;
leukaemia and anti-CD52 antibody composition;
NHL and anti-CD20 antibody composition;
cancer and anti-HER1 antibody composition;
lung, colorectal, and kidney cancers and anti VEGF antibody composition;
non-Hodgkin's lymphoma and anti-CD22 antibody composition;
breast, ovarian, prostate cancers and bispecific HER2Neu/CD64 antibody composition;
small cell lung carcinoma and anti-GD3 antibody composition;
ovarian cancer and anti-CA125 antibody composition;
malignant melanoma and anti-GD antibody composition;
cancers and EGF antibody composition;
cancers and anti-GD2 antibody composition; and
prostate cancer and anti-PSMA composition.